Trial Details

Not Recruiting
Basic Information
Clinical ID c5512
Identifier ACTRN12609000571279
Trial Title Prospective non controlled study of immunogenicity of Human Papilloma Virus (HPV) Vaccine in groups at special risk of poor vaccine result
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Special Risk Groups1. Paediatric Rheumatalogical Disease2. Inflammatory Bowel Disease3. Acute Lymphoblastic Leukaemia4. Solid Organ Transplant Recipients (kidney and liver)5.
Interventions Licensed quadrivalent HPV vaccine.The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
Participant Information
Sponsor National Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation
City NULL
Country/Region Australia
Enrollment Criteria
Sex Requirement FEMALE
Age Requirement ADULT, CHILD, TEENAGER
Study Design
Study Type Interventional
Phase PHASE3
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL